Elicio Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Elicio Therapeutics
ELTX Stock   7.60  0.48  5.94%   
Elicio Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Elicio Therapeutics' valuation are provided below:
Market Capitalization
131.2 M
Earnings Share
(3.11)
We have found one hundred twenty available fundamental signals for Elicio Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Elicio Therapeutics prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 58.8 M in 2026. Enterprise Value is likely to rise to about 66.8 M in 2026

Elicio Therapeutics Total Revenue

0.0

Check Elicio Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elicio Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 764.6 K, Interest Expense of 389 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.57, Dividend Yield of 0.0 or Days Sales Outstanding of 8.88. Elicio financial statements analysis is a perfect complement when working with Elicio Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Elicio Stock
Check out the analysis of Elicio Therapeutics Correlation against competitors.
For more information on how to buy Elicio Stock please use our How to Invest in Elicio Therapeutics guide.

Elicio Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets34.5 M32.4 M28.1 M
Slightly volatile
Short and Long Term Debt Total20.9 M29.9 M15.7 M
Slightly volatile
Other Current Liabilities6.4 M9.7 M5.7 M
Slightly volatile
Total Current Liabilities22.4 M13.3 M14.7 M
Slightly volatile
Property Plant And Equipment Net5.9 M7.1 M4.4 M
Pretty Stable
Accounts Payable1.1 M1.2 M2.1 M
Slightly volatile
Cash24 M20.3 M20.3 M
Slightly volatile
Non Current Assets Total8.1 M8.6 M6.2 M
Pretty Stable
Cash And Short Term Investments24 M20.3 M20.3 M
Slightly volatile
Net Receivables1.4 M926.9 K806.6 K
Slightly volatile
Common Stock Shares Outstanding14.7 M14 M4.9 M
Slightly volatile
Liabilities And Stockholders Equity34.5 M32.4 M28.1 M
Slightly volatile
Non Current Liabilities Total33.8 M32.2 M9.9 M
Slightly volatile
Other Current Assets3.7 M3.5 M1.2 M
Slightly volatile
Other Stockholder Equity220.8 M210.3 M83.7 M
Slightly volatile
Total Liabilities33.4 M45.4 M23.3 M
Slightly volatile
Total Current Assets26.4 M23.8 M21.9 M
Slightly volatile
Short Term Debt770.4 K810.9 K7.5 M
Very volatile
Common Stock104.5 K126.5 K86.1 K
Slightly volatile
Property Plant And Equipment Gross5.6 M8.9 M3.6 M
Slightly volatile
Capital Stock132.9 K126.5 K78.9 K
Slightly volatile
Property Plant Equipment10.3 M9.8 M3.6 M
Slightly volatile
Other Liabilities67 K105.8 K47.4 K
Slightly volatile
Short and Long Term Debt9.4 M10.6 M11.6 M
Slightly volatile
Non Current Liabilities Other67 K105.8 K47.4 K
Slightly volatile
Long Term Debt16 M18 M19.7 M
Slightly volatile

Elicio Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization764.6 K1.4 M547.6 K
Slightly volatile
Interest Expense389 K409.5 K4.1 M
Pretty Stable
Other Operating Expenses37.1 M51.7 M28.3 M
Slightly volatile
Cost Of Revenue1.3 M1.1 M1.5 M
Slightly volatile
Total Operating Expenses35.3 M50.4 M26.7 M
Slightly volatile
Income Tax Expense4.3 M4.1 M1.3 M
Slightly volatile
Research Development27.5 M38.7 M17.8 M
Slightly volatile
Interest Income938.2 K893.5 K227.9 K
Slightly volatile
Selling General Administrative7.7 M13 M5.2 M
Slightly volatile
Reconciled Depreciation1.4 M1.4 M414.4 K
Slightly volatile

Elicio Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow10.2 M16.4 M7 M
Slightly volatile
Depreciation697.4 K1.4 M511.3 K
Slightly volatile
Other Non Cash Items7.5 M9.5 M6.7 M
Pretty Stable
End Period Cash Flow14.8 M22.4 M15.5 M
Slightly volatile
Stock Based Compensation1.8 M1.7 M529.8 K
Slightly volatile
Issuance Of Capital Stock9.3 M5.1 M8.3 M
Pretty Stable
Change To Netincome6.2 M5.9 M1.8 M
Slightly volatile
Other Cashflows From Investing Activities2.6 K2.7 K28.5 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.570.64.3738
Very volatile
Days Sales Outstanding8.889.3556.7041
Very volatile
Stock Based Compensation To Revenue0.01740.01960.0214
Slightly volatile
Capex To Depreciation0.06310.06650.3711
Very volatile
Payables Turnover1.241.318.5606
Slightly volatile
Research And Ddevelopement To Revenue1.471.553.2291
Pretty Stable
Capex To Revenue0.03270.01670.0669
Pretty Stable
Cash Per Share1.581.6665.3122
Slightly volatile
Days Payables Outstanding275289704
Slightly volatile
Income Quality1.350.821.2818
Slightly volatile
Current Ratio1.91.622.5048
Very volatile
Receivables Turnover33.1931.6126.4002
Slightly volatile
Capex Per Share0.00780.00821.5803
Slightly volatile
Revenue Per Share9.6710.17277
Slightly volatile
Interest Debt Per Share2.372.5222
Slightly volatile
Debt To Assets0.721.060.7374
Pretty Stable
Graham Number602849850
Slightly volatile
Operating Cycle8.889.3556.7041
Very volatile
Days Of Payables Outstanding275289704
Slightly volatile
Effective Tax Rate0.180.240.239
Slightly volatile
Quick Ratio1.91.622.5048
Very volatile
Net Income Per E B T0.30.440.4234
Slightly volatile
Cash Ratio1.681.382.2581
Very volatile
Days Of Sales Outstanding8.889.3556.7041
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9808
Pretty Stable
Fixed Asset Turnover6.035.742.6013
Slightly volatile
Debt Ratio0.721.060.7374
Pretty Stable
Price Sales Ratio0.570.64.3738
Very volatile
Asset Turnover0.340.29330.3162
Slightly volatile
Gross Profit Margin0.460.860.7227
Slightly volatile

Elicio Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap58.8 M56 M27.9 M
Slightly volatile

Elicio Fundamental Market Drivers

Elicio Upcoming Events

15th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Elicio Therapeutics Financial Statements

Elicio Therapeutics investors use historical fundamental indicators, such as Elicio Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Elicio Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.3 M1.1 M
Cost Of Revenue1.1 M1.3 M
Stock Based Compensation To Revenue 0.02  0.02 
Research And Ddevelopement To Revenue 1.55  1.47 
Capex To Revenue 0.02  0.03 
Revenue Per Share 10.17  9.67 
Ebit Per Revenue(1.60)(1.68)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VGIAXVanguard Growth And
XARSPDR SP Aerospace
XARSPDR SP Aerospace

Additional Tools for Elicio Stock Analysis

When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY